StockData
Tyra Biosciences, Inc. logo

Tyra Biosciences, Inc. (TYRA) stock

TYRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$19.57−0.17 (-0.86%)

Close on Nov 17, 2026Market cap $1.17BP/E –Yield –

Tyra Biosciences r&d expenses

Research and development expenses are spending on new products and technology.

Tyra Biosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $126.32M, up 34.2% year over year. For fiscal 2025 it was $102.93M, up 28.5% from the year before. The highest annual figure on record is $102.93M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$102.93M+28.5%
FY2024Dec 31, 2024$80.08M+28.1%
FY2023Dec 31, 2023$62.52M+45.4%
FY2022Dec 31, 2022$43.01M+108.4%
FY2021Dec 31, 2021$20.64M+186.5%
FY2020Dec 31, 2020$7.20M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$39.20M+61.2%
Q1 FY2026Mar 31, 2026$33.47M+34.1%
Q4 FY2025Dec 31, 2025$28.19M+27.1%
Q3 FY2025Sep 30, 2025$25.47M+12.2%
Q2 FY2025Jun 30, 2025$24.31M+35.1%
Q1 FY2025Mar 31, 2025$24.96M+45.1%
Q4 FY2024Dec 31, 2024$22.18M+7.3%
Q3 FY2024Sep 30, 2024$22.70M+17.8%
Q2 FY2024Jun 30, 2024$18.00M+48.0%
Q1 FY2024Mar 31, 2024$17.20M+65.3%
Q4 FY2023Dec 31, 2023$20.68M+98.8%
Q3 FY2023Sep 30, 2023$19.27M+76.6%
Q2 FY2023Jun 30, 2023$12.16M+1.0%
Q1 FY2023Mar 31, 2023$10.41M+7.9%
Q4 FY2022Dec 31, 2022$10.40M+43.4%
Q3 FY2022Sep 30, 2022$10.92M+99.0%
Q2 FY2022Jun 30, 2022$12.05M+175.0%
Q1 FY2022Mar 31, 2022$9.65M+173.9%
Q4 FY2021Dec 31, 2021$7.25M+147.6%
Q3 FY2021Sep 30, 2021$5.48M+194.5%
Q2 FY2021Jun 30, 2021$4.38M–
Q1 FY2021Mar 31, 2021$3.52M–
Q4 FY2020Dec 31, 2020$2.93M–
Q3 FY2020Sep 30, 2020$1.86M–

More Tyra Biosciences figures

See a number that looks wrong?